Tom Radivoyevitch
Tom Radivoyevitch
Verified email at
Cited by
Cited by
Dynamics of clonal evolution in myelodysplastic syndromes
H Makishima, T Yoshizato, K Yoshida, MA Sekeres, T Radivoyevitch, ...
Nature genetics 49 (2), 204-212, 2017
Dynamics of clonal evolution in myelodysplastic syndromes
H Makishima, T Yoshizato, K Yoshida, MA Sekeres, T Radivoyevitch, ...
Nature genetics 49 (2), 204-212, 2017
12 Gy gamma knife radiosurgical volume is a predictor for radiation necrosis in non-AVM intracranial tumors
T Korytko, T Radivoyevitch, V Colussi, BW Wessels, K Pillai, RJ Maciunas, ...
International Journal of Radiation Oncology* Biology* Physics 64 (2), 419-424, 2006
Genetic alterations of the cohesin complex genes in myeloid malignancies
S Thota, AD Viny, H Makishima, B Spitzer, T Radivoyevitch, ...
Blood, The Journal of the American Society of Hematology 124 (11), 1790-1798, 2014
The driver and passenger effects of isocitrate dehydrogenase 1 and 2 mutations in oncogenesis and survival prolongation
RJ Molenaar, T Radivoyevitch, JP Maciejewski, CJF van Noorden, ...
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1846 (2), 326-341, 2014
SBML Level 3: an extensible format for the exchange and reuse of biological models
SM Keating, D Waltemath, M König, F Zhang, A Dräger, C Chaouiya, ...
Molecular systems biology 16 (8), e9110, 2020
Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis
TJ Alban, AG Alvarado, MD Sorensen, D Bayik, J Volovetz, E Serbinowski, ...
JCI insight 3 (21), 2018
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
A Nazha, M Narkhede, T Radivoyevitch, DJ Seastone, BJ Patel, AT Gerds, ...
Leukemia 30 (11), 2214-2220, 2016
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer
MM Cooney, T Radivoyevitch, A Dowlati, B Overmoyer, N Levitan, ...
Clinical Cancer Research 10 (1), 96-100, 2004
Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198
RJ Molenaar, D Botman, MA Smits, VV Hira, SA van Lith, J Stap, ...
Cancer research 75 (22), 4790-4802, 2015
Biochemical systems analysis of genome-wide expression data
EO Voit, T Radivoyevitch
Bioinformatics 16 (11), 1023-1037, 2000
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy
RZ Mahfouz, A Jankowska, Q Ebrahem, X Gu, V Visconte, A Tabarroki, ...
Clinical cancer research 19 (4), 938-948, 2013
Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer
RJ Molenaar, S Sidana, T Radivoyevitch, AS Advani, AT Gerds, ...
Journal of clinical oncology 36 (18), 1831, 2018
Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study
R Molokie, D Lavelle, M Gowhari, M Pacini, L Krauz, J Hassan, V Ibanez, ...
PLoS medicine 14 (9), e1002382, 2017
Tet2 loss leads to hypermutagenicity in haematopoietic stem/progenitor cells
F Pan, TS Wingo, Z Zhao, R Gao, H Makishima, G Qu, L Lin, M Yu, ...
Nature communications 8 (1), 15102, 2017
Bleeding incidence and risk factors among cancer patients treated with anticoagulation
DE Angelini, T Radivoyevitch, KR McCrae, AA Khorana
American journal of hematology 94 (7), 780-785, 2019
Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates
X Gu, Q Ebrahem, RZ Mahfouz, M Hasipek, F Enane, T Radivoyevitch, ...
The Journal of clinical investigation 128 (10), 4260-4279, 2018
Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
RJ Molenaar, S Thota, Y Nagata, B Patel, M Clemente, B Przychodzen, ...
Leukemia 29 (11), 2134-2142, 2015
Reduced expression of NFAT-associated genes in UCB versus adult CD4+ T lymphocytes during primary stimulation
BA Kaminski, S Kadereit, RE Miller, P Leahy, KR Stein, DA Topa, ...
Blood 102 (13), 4608-4617, 2003
IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
RJ Molenaar, T Radivoyevitch, Y Nagata, M Khurshed, B Przychodzen, ...
Clinical cancer research 24 (7), 1705-1715, 2018
The system can't perform the operation now. Try again later.
Articles 1–20